Global Market Bulletin
  • Home
  • Stock Market News
  • Investing
  • Economy
  • CEO Interviews
  • Contact Us
No Result
View All Result
SUBSCRIBE
Global Market Bulletin
  • Home
  • Stock Market News
  • Investing
  • Economy
  • CEO Interviews
  • Contact Us
No Result
View All Result
Global Market Bulletin
No Result
View All Result
Home Stock Market News

Top 5 Agentic AI Stocks That Could Deliver 100% Returns

by Global Market Bulletin
April 11, 2026
in Stock Market News
0
Top 5 Agentic AI Stocks That Could Deliver 100% Returns

Top 5 Agentic AI Stocks That Could Deliver 100% Returns

232
SHARES
505
VIEWS
Share on FacebookShare on Twitter

In this article, we break down the Top 5 Agentic AI Stocks That Could Deliver 100% Returns. For investors looking for the complete list, you can explore our full report on the Top 10 Agentic AI Stocks That Could Deliver 100% Returns.

You might also like

Can Immunovant (IMVT) Turn Its Rheumatoid Arthritis Trial Win Into a Bigger FDA Story?

Here’s Why T1 Energy (TE) Could Be a Controversial Bet on U.S. Solar Manufacturing

Can Xanadu Quantum Technologies (XNDU) Recover as Investors Bet on the Future of Quantum Computing?

5. ServiceNow Inc. (NYSE:NOW)

ServiceNow has long been considered one of the most structurally important players in enterprise software, and its aggressive pivot into agentic AI is beginning to reshape how investors view its long-term growth potential. Unlike smaller companies that are still trying to establish product-market fit, ServiceNow is layering AI capabilities onto an already deeply embedded workflow infrastructure—a strategy that often leads to faster monetization and stronger customer retention.

Still, the market has shown a degree of caution. In early April 2026, Stifel trimmed its price target, citing softer channel checks and weakness in U.S. federal spending. This serves as a reminder that even the strongest AI narratives cannot fully insulate companies from macroeconomic pressures. For disciplined investors, this tension between strong innovation and near-term headwinds often creates the kind of mispricing opportunities that define long-term winners.

Operationally, however, the numbers remain difficult to ignore. ServiceNow reported fourth-quarter subscription revenue of $3.47 billion, up 21% year over year, with total revenue climbing to $3.57 billion. Even more compelling is its current remaining performance obligation of $12.85 billion, which surged 25%—a clear signal of strong forward demand and revenue visibility.

The company’s collaboration with OpenAI further strengthens its agentic AI positioning. By embedding advanced models directly into its platform, ServiceNow is enabling enterprises to deploy autonomous agents across IT, HR, and customer service workflows. With more than 80 billion workflows already running annually on its system, the company is not building from scratch—it is transforming an existing enterprise backbone into an AI-driven execution engine.

Click next to see the following stock...

Page 1 of 5
12...5Next
Tags: Appier Group Inc. (OTC:APGRF)Daily NewsletterHubSpot Inc. (NYSE:HUBS)NASDAQ:PLTRNASDAQ:SOUNNYSE:HUBSNYSE:NOWOTC:APGRFPalantir Technologies Inc. (NASDAQ:PLTR)ServiceNow Inc. (NYSE:NOW)SoundHound AI Inc. (NASDAQ:SOUN)Top 5 Agentic AI Stocks That Could Deliver 100% ReturnsYahoo Finance
Share93Tweet58

Global Market Bulletin

Global Market Bulletin is a leading provider of stock market updates, economic news, and personalized investing guides. Our team brings you the latest global financial information to help you make smart investment decisions. About the Editorial Team Our editorial team consists of financial experts and seasoned market analysts who bring decades of experience to our coverage. With a commitment to unbiased reporting, our team ensures that every article is backed by thorough research and delivers accurate financial insights.

Recommended For You

Can Immunovant (IMVT) Turn Its Rheumatoid Arthritis Trial Win Into a Bigger FDA Story?

by Global Market Bulletin
May 21, 2026
0
Can Immunovant (IMVT) Turn Its Rheumatoid Arthritis Trial Win Into a Bigger FDA Story?

We recently published our article Top 5 Stocks Delivering Big-Time Gains Today. To read the full story, you can go directly to Top 10 Stocks Delivering Big-Time Gains Today. In...

Read moreDetails

Here’s Why T1 Energy (TE) Could Be a Controversial Bet on U.S. Solar Manufacturing

by Global Market Bulletin
May 21, 2026
0
Here’s Why T1 Energy (TE) Could Be a Controversial Bet on U.S. Solar Manufacturing

We recently published our article Top 5 Stocks Delivering Big-Time Gains Today. To read the full story, you can go directly to Top 10 Stocks Delivering Big-Time Gains Today. In...

Read moreDetails

Can Xanadu Quantum Technologies (XNDU) Recover as Investors Bet on the Future of Quantum Computing?

by Global Market Bulletin
May 21, 2026
0
Can Xanadu Quantum Technologies (XNDU) Recover as Investors Bet on the Future of Quantum Computing?

We recently published our article Top 5 Stocks Delivering Big-Time Gains Today. To read the full story, you can go directly to Top 10 Stocks Delivering Big-Time Gains Today. In...

Read moreDetails

Here’s What Makes Navitas Semiconductor (NVTS) a Risky but Exciting AI Power Stock

by Global Market Bulletin
May 21, 2026
0
Here’s What Makes Navitas Semiconductor (NVTS) a Risky but Exciting AI Power Stock

We recently published our article Top 5 Stocks Delivering Big-Time Gains Today. To read the full story, you can go directly to Top 10 Stocks Delivering Big-Time Gains Today. In...

Read moreDetails

Is Astera Labs (ALAB) Still a Smart AI Stock to Buy After Hitting a New All-Time High?

by Global Market Bulletin
May 21, 2026
0
Is Astera Labs (ALAB) Still a Smart AI Stock to Buy After Hitting a New All-Time High?

We recently published our article Top 5 Stocks Delivering Big-Time Gains Today. To read the full story, you can go directly to Top 10 Stocks Delivering Big-Time Gains Today. In...

Read moreDetails

Browse by Category

  • CEO Interviews
  • Economy
  • Investing
  • Stock Market News
  • Uncategorized

QUICK LINKS

  • Stock Market News
  • Investing
  • Economy
  • Contact Us
  • About Global Market Bulletin
  • Editorial Policy – Global Market Bulletin
  • Our Editorial Team

RECENT POSTS

  • Can Immunovant (IMVT) Turn Its Rheumatoid Arthritis Trial Win Into a Bigger FDA Story?
  • Here’s Why T1 Energy (TE) Could Be a Controversial Bet on U.S. Solar Manufacturing
  • Can Xanadu Quantum Technologies (XNDU) Recover as Investors Bet on the Future of Quantum Computing?

GET EMAIL MARKET UPDATES

Subscribe to our mailing list to receives daily updates direct to your inbox!
  • Privacy Policy
  • Terms and Conditions

© 2022 Global Market Bulletin. All Rights Reserved.

No Result
View All Result
  • Home
  • Stock Market News
  • Investing
  • Economy

© 2022 Global Market Bulletin. All Rights Reserved.

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?